RevBio Receives Approval to Start a Dental Clinical Trial in Italy for its Regenerative Biomaterial
RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117006135/en/
Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)
This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.
“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”
Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.
Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.”
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117006135/en/
About Business Wire
24 Martin Lane
EC4R 0DR London
+44 20 7626 1982http://www.businesswire.co.uk
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Ukraine to the Whole of Europe: Cyber Conflict Reaches a Turning Point29.3.2023 09:00:00 CEST | Press release
Thales: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005023/en/ (Photo: Thales) Eastern and Northern Europe on the front lines of the cyber conflict A new attack geography has taken shape over the last 12 months. At the very beginning of the conflict, the majority of incidents only affected Ukraine (50.4% in the first quarter of 2022 versus 28.6% in the third quarter), but EU countries have seen a sharp increase in conflict-related incidents in the last six months (9.8% versus 46.5% of global attacks). In the summer of 2022, there were almost as many conflict-related incidents in EU countries as there were in Ukraine (85 versus 86), and in the first quarter of 2023, the overwhelming majority of incidents (80.9%) have been inside the European Union. Candidates for European integration such as Montenegro and Moldova are being increasingly targeted (0.7% of attacks in the first quarter of 2022 versus 2.7% at the end of
Zone Adopts ThetaRay AI Solution to Monitor and Screen Payments in Nigeria29.3.2023 09:00:00 CEST | Press release
Zone (formerly Appzone), Africa’s first regulated layer-1 blockchain network for payments, and ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced they will collaborate to implement ThetaRay’s cloud-based SONAR solution to monitor and screen Zone’s transactions in Nigeria for illicit activities and sanctions violations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230329005222/en/ Zone is Africa's first Layer-1 blockchain network for payments. (Graphic: Business Wire) Headquartered in Lagos, Zone serves large commercial banks, payment fintechs, digital banks, and OFIs with real-time, low-cost settlement of both fiat and digital currencies for domestic and cross-border payments. Through the agreement, ThetaRay will provide Zone the SaaS-based SONAR AI solution that can detect and prevent the earliest signs of sophisticated attempts to launder money or circumvent financial sanctions
Merz Aesthetics Highlights Emerging Trends in Regenerative Aesthetics and its Innovative Portfolio at the 2023 Aesthetic and Anti-aging Medicine World Congress (AMWC)29.3.2023 09:00:00 CEST | Press release
Merz Aesthetics, a global leader in aesthetic medicine, is presenting a total of 15 posters at the 2023 Aesthetic and Anti-Aging Medicine World Congress (AMWC), highlighting its medical aesthetics product portfolio as well as new trends in aesthetic medicine. AMWC is a leading global scientific conference specializing in aesthetic and anti-aging medicine, and this year’s congress will be a hybrid event allowing participants to attend live in Monaco or virtually from March 30 until April 1, 2023. “Merz Aesthetics is looking forward to highlighting our advancing science and leadership within the medical aesthetics industry at this year’s AMWC, including insights on the evolving field of regenerative aesthetics,” said Terri Phillips, M.D., Chief Medical Affairs Officer, Merz Aesthetics. “We take great pride in the quality and innovation of our product portfolio and are thrilled to present additional evidence that further strengthens the established safety profile across our portfolio.” “T
HALO Space Announces Second Test Flight, Accelerating Mission to Transform Space Tourism29.3.2023 08:00:00 CEST | Press release
HALO Space, a global space tourism company developed via Arthur D. Little’s Breakthrough Incubator Program, has announced the next stage of its journey towards the launch of its innovative edge-of-space experience. HALO Space’s second test will take place in southern Spain this year after its first test flight in India was completed successfully last December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005926/en/ HALO Space Announces Second Test Flight, Accelerating Mission to Transform Space Tourism (Photo: Business Wire) HALO Space is committed to enabling 10,000 passengers in this decade to experience the “Overview Effect”, where both the Earth’s curvature and the darkness of space can be observed. From 2025, HALO Space will lift eight passengers per flight up to 40 kilometers into the stratosphere for a transformative experience that will last four to six hours. With a mission to offer safe, sustainable and eco
World’s Major Economies Playing Catch-Up as Widespread Adoption Drives Global Real-Time Payments Growth – ACI Worldwide Report29.3.2023 03:30:00 CEST | Press release
New sophisticated use cases for consumers and businesses are driving global RTP volumes to record highs, with 195.0B RTP transactions recorded globally in 2022 — a YoY growth of 63.2% — according to the 2023 Prime Time for Real-Time report, published by ACI Worldwide (NASDAQ: ACIW), a global leader in mission-critical, real-time payments software, in partnership with GlobalData, a leading data and analytics company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230328005314/en/ Prime Time for Real-Time 2023 : Key Facts and Figures at a Glance (Graphic: Business Wire) 511.7B real-time transactions globally are forecast by 2027, representing a 2022-2027 compound annual growth rate (CAGR) of 21.3%. By 2027, RTPs are expected to account for 27.8% of all electronic payments globally. India remains the undisputed RTP leader, with a staggering 89.5B transactions in 2022 and a YoY growth rate of 76.8%. India accounted for 46% of al